Is miragen Therapeutics stock a good buy?
Is miragen Therapeutics stock a good buy?
Miragen Therapeutics has received a consensus rating of Buy. The company’s average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.
Is Mgen stock a good buy?
If you are looking for stocks with good return, Miragen Therapeutics Inc can be a profitable investment option. Based on our forecasts, a long-term increase is expected, the “MGEN” stock price prognosis for 2026-03-18 is 66.242 USD. With a 5-year investment, the revenue is expected to be around +268.01%.
What does miragen therapeutics do?
miRagen Therapeutics is a biotechnology company advancing new treatments for patients with diseases that are underserved by today’s therapies. miRagen’s most advanced program, VRDN-001, is a clinical-stage anti-IGF-1R monoclonal antibody in development for thyroid eye disease (TED).
Why is Mgen stock up?
A bit of mergers and acquisitions (M&A) news has Miragen Therapeutics (NASDAQ:MGEN) stock skyrocketing on Wednesday. This is due to the company announcing the acquisition of Viridian Therapeutics, a private biotech firm that focuses on advancing new treatments for patients with underserved diseases.
Did Mgen stock split?
Miragen Therapeutics, Inc. (MGEN) will effect a one-for-fifteen (1-15) reverse split of its common stock. The reverse stock split will become effective on Friday, November 13, 2020. In conjunction with the reverse split, the CUSIP number will change to 60463E202.
What happened miRagen Therapeutics?
BOULDER, Colo., Jan. 19, 2021 (GLOBE NEWSWIRE) — miRagen Therapeutics, Inc. (NASDAQ: MGEN), a development-stage biotechnology company, today announced its name change to Viridian Therapeutics, Inc. (“Viridian”).
What happened to miragen?
BOULDER, Colo., Jan. 19, 2021 (GLOBE NEWSWIRE) — miRagen Therapeutics, Inc. (NASDAQ: MGEN), a development-stage biotechnology company, today announced its name change to Viridian Therapeutics, Inc. Rauch will remain as strategic advisor for the Company.
Is DXC stock a buy?
DXC Technology has received a consensus rating of Buy. The company’s average rating score is 2.64, and is based on 8 buy ratings, 2 hold ratings, and 1 sell rating.
Did Mgen reverse split?
Where can I buy shares of miRagen Therapeutics?
Shares of MGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
When did miRagen Therapeutics acquire Viridian Therapeutics?
and WALTHAM, Mass., Oct. 28, 2020 (GLOBE NEWSWIRE) — miRagen Therapeutics, Inc. (“miRagen”) (NASDAQ: MGEN) today announced it has completed the acquisition of Viridian Therapeutics, Inc. (“Viridian”), a privately held biotechnology company focused on advancing new treatments for patients with diseases that are underserved by today’s therapies.
When do CVR’s go out for miRagen Therapeutics?
In connection with the transactions announced today, a non-transferrable contingent value right (“CVR”) is expected to be distributed to holders of miRagen common stock within the next 30 days.
When does miRagen expect to start a TED clinical trial?
Pending feedback from regulatory authorities, miRagen expects to initiate a Phase 2 clinical trial of VRDN-001 in TED in 2021. Worldwide rights to develop and commercialize VRDN-001 for all non-oncology indications that do not use radiopharmaceuticals, including the treatment of TED, were exclusively licensed by Viridian from ImmunoGen, Inc.
https://www.youtube.com/watch?v=UqV_gsK7DB0